Pharmaceutics | |
Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles | |
Antonietta Vilella1  Barbara Ruozi2  Daniela Belletti2  Francesca Pederzoli2  Marianna Galliani2  Valentina Semeghini1  Flavio Forni2  Michele Zoli2  Maria Angela Vandelli2  Giovanni Tosi2  | |
[1] Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41124, Italy; E-Mails:;Nanomedicine Group, Te.Far.T.I. Center, Department of Life Sciences, University of Modena and Reggio Emilia, Modena 41124, Italy; E-Mails: | |
关键词: nanomedicine; blood brain barrier; neuron; endocytosis; cellular uptake; | |
DOI : 10.3390/pharmaceutics7020074 | |
来源: mdpi | |
【 摘 要 】
The success of nanomedicine as a new strategy for drug delivery and targeting prompted the interest in developing approaches toward basic and clinical neuroscience. Despite enormous advances on brain research, central nervous system (CNS) disorders remain the world’s leading cause of disability, in part due to the inability of the majority of drugs to reach the brain parenchyma. Many attempts to use nanomedicines as CNS drug delivery systems (DDS) were made; among the various non-invasive approaches, nanoparticulate carriers and, particularly, polymeric nanoparticles (NPs) seem to be the most interesting strategies. In particular, the ability of poly-lactide-co-glycolide NPs (PLGA-NPs) specifically engineered with a glycopeptide (g7), conferring to NPs’ ability to cross the blood brain barrier (BBB) in rodents at a concentration of up to 10% of the injected dose, was demonstrated in previous studies using different routes of administrations. Most of the evidence on NP uptake mechanisms reported in the literature about intracellular pathways and processes of cell entry is based on
【 授权许可】
CC BY
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190010544ZK.pdf | 1628KB | download |